JPMorgan Chase & Co. cut its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 27.6% during the 1st quarter, HoldingsChannel reports. The fund owned 51,167 shares of the biotechnology company’s stock after selling 19,520 shares during the quarter. JPMorgan Chase & Co.’s holdings in AnaptysBio were worth $5,325,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in ANAB. BlackRock Inc. grew its stake in AnaptysBio by 104.1% during the fourth quarter. BlackRock Inc. now owns 1,393,305 shares of the biotechnology company’s stock worth $140,334,000 after buying an additional 710,574 shares in the last quarter. Farallon Capital Management LLC grew its stake in AnaptysBio by 128.0% during the fourth quarter. Farallon Capital Management LLC now owns 561,000 shares of the biotechnology company’s stock worth $56,504,000 after buying an additional 315,000 shares in the last quarter. Redmile Group LLC acquired a new stake in AnaptysBio during the fourth quarter worth about $23,150,000. VHCP Management II LLC grew its stake in AnaptysBio by 68.6% during the fourth quarter. VHCP Management II LLC now owns 282,550 shares of the biotechnology company’s stock worth $28,458,000 after buying an additional 115,000 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in AnaptysBio by 83.6% during the fourth quarter. Deutsche Bank AG now owns 192,361 shares of the biotechnology company’s stock worth $19,373,000 after buying an additional 87,566 shares in the last quarter.
A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of AnaptysBio from $130.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday, March 6th. Wedbush restated an “outperform” rating and issued a $151.00 price target on shares of AnaptysBio in a research note on Tuesday, March 27th. JMP Securities set a $180.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research note on Tuesday, March 27th. Royal Bank of Canada downgraded shares of AnaptysBio from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $144.00 to $40.00 in a research note on Wednesday, April 4th. Finally, Zacks Investment Research downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research note on Friday, May 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. AnaptysBio presently has an average rating of “Buy” and a consensus target price of $131.44.
In related news, Director Nicholas Lydon sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $86.88, for a total value of $2,867,040.00. Following the completion of the transaction, the director now owns 301,506 shares in the company, valued at approximately $26,194,841.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 20.80% of the stock is owned by company insiders.
ANAB opened at $71.04 on Friday. AnaptysBio Inc has a 1-year low of $20.12 and a 1-year high of $134.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.57 and a quick ratio of 17.57.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.19). During the same quarter in the prior year, the business posted ($0.75) EPS. sell-side analysts predict that AnaptysBio Inc will post -3.04 earnings per share for the current year.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.